UY39342A - Tratamiento con poziotinib para el cáncer de pulmón de células no pequeñas - Google Patents

Tratamiento con poziotinib para el cáncer de pulmón de células no pequeñas

Info

Publication number
UY39342A
UY39342A UY0001039342A UY39342A UY39342A UY 39342 A UY39342 A UY 39342A UY 0001039342 A UY0001039342 A UY 0001039342A UY 39342 A UY39342 A UY 39342A UY 39342 A UY39342 A UY 39342A
Authority
UY
Uruguay
Prior art keywords
poziotinib
therapy
lung cancer
small cell
cell lung
Prior art date
Application number
UY0001039342A
Other languages
English (en)
Inventor
Gajanan Bhat
Francois Lebel
Sribalaji Lakshmikanthan
A Barrett John
Original Assignee
Spectrum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals Inc filed Critical Spectrum Pharmaceuticals Inc
Publication of UY39342A publication Critical patent/UY39342A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona un método para tratar NSCLC en un sujeto. El método generalmente incluye administrar una cantidad terapéuticamente eficaz de poziotinib o una sal farmacéuticamente aceptable del mismo a un sujeto que lo necesite. El poziotinib exhibe eficacias mejoradas en sujetos con ciertas mutaciones del exón 20 de EGFR o HER2, que dan como resultado resistencia a los inhibidores de tirosina quinasa convencionales.
UY0001039342A 2020-07-27 2021-07-27 Tratamiento con poziotinib para el cáncer de pulmón de células no pequeñas UY39342A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063056895P 2020-07-27 2020-07-27
US202063199446P 2020-12-29 2020-12-29
US202163155123P 2021-03-01 2021-03-01
US202163166722P 2021-03-26 2021-03-26

Publications (1)

Publication Number Publication Date
UY39342A true UY39342A (es) 2022-02-25

Family

ID=80036135

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039342A UY39342A (es) 2020-07-27 2021-07-27 Tratamiento con poziotinib para el cáncer de pulmón de células no pequeñas

Country Status (3)

Country Link
TW (1) TW202211923A (es)
UY (1) UY39342A (es)
WO (1) WO2022026442A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY39593A (es) * 2020-12-29 2022-07-29 Spectrum Pharmaceuticals Inc Tratamiento para tumores sólidos malignos

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106588943B (zh) * 2015-10-19 2018-10-16 广东东阳光药业有限公司 一种egfr抑制剂的盐、晶型及其用途
CU20190051A7 (es) * 2016-11-17 2020-01-03 Univ Texas Compuestos con actividad antitumoral contra células cancerosas que tienen mutaciones en el exón 20 de egfr o her2
CN111818925B (zh) * 2018-05-23 2023-12-12 江苏恒瑞医药股份有限公司 Cdk4/6抑制剂与egfr抑制剂联合在制备治疗肿瘤疾病的药物中的用途
WO2020052575A1 (zh) * 2018-09-12 2020-03-19 江苏恒瑞医药股份有限公司 Jak激酶抑制剂与egfr抑制剂联合在制备治疗肿瘤疾病的药物中的用途

Also Published As

Publication number Publication date
WO2022026442A1 (en) 2022-02-03
TW202211923A (zh) 2022-04-01

Similar Documents

Publication Publication Date Title
ECSP19043254A (es) Compuestos con actividad antitumoral contra células cancerosas que tienen mutaciones en el exón 20 de egfr o her2
MX2021005011A (es) Métodos de tratamiento del cáncer en pacientes identificados por biomarcadores con inhibidores no covalentes de cinasa 7 dependiente de ciclina (cdk7).
MX2021005651A (es) Combinacion farmaceutica para el tratamiento contra el cancer.
AR095197A1 (es) Combinación de un inhibidor de egfr t790m y un inhibidor de egfr para el tratamiento del cáncer pulmonar de células no pequeñas
BR112016028641A2 (pt) ?método para tratar câncer?
WO2018102687A3 (en) Combination therapy for treating cancer
BR112021006318A2 (pt) terapia de combinação para o tratamento de câncer
UY39342A (es) Tratamiento con poziotinib para el cáncer de pulmón de células no pequeñas
PH12021551276A1 (en) Combination therapy for the treatment of cancer
MX2021012705A (es) Compuestos con actividad antitumoral contra las celulas cancerosas que portan mutaciones en el receptor del factor de crecimiento epidermico (egfr) resistentes al inhibidor de la tirosina quinasa.
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
CL2022002682A1 (es) Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres
MX2024006168A (es) Composicion farmaceutica y uso de la misma.
BR112022009470A2 (pt) Regime de tratamento diário para o câncer com um inibidor de prmt5
AR049135A1 (es) Composicion,metodo, kit y tratamiento con oxaliplatino y un inhibidor del egfr,como erlotinib
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
CL2022000781A1 (es) Tratamientos cognitivos medicinales
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
AR123058A1 (es) Tratamiento con poziotinib para el cáncer de pulmón de células no pequeñas
JOP20210221A1 (ar) علاجات مشتركة لاستخدامها في علاج السرطان
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
BR112023023674A2 (pt) Compostos macrocíclicos e seus usos
UY39593A (es) Tratamiento para tumores sólidos malignos
MX2021001764A (es) Terapia de combinacion.
BR112022003286A2 (pt) Combinação de poziotinibe com inibidores de vegfr2 e métodos de uso da mesma